Bayer claims another win on its CKD and diabetes hopeful, though the question remains over just how big it is
After earning priority review for a top CKD and diabetes program back in January, Bayer is revealing more data that it hopes will boost its pitch to regulators.
Bayer’s finerenone has passed another Phase III test, the pharma announced Monday, saying the candidate met the primary endpoint in a second study evaluating treatment for CKD and type 2 diabetes. The difference here is this study included more patients with earlier stages of the disease than the first trial.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.